304 related articles for article (PubMed ID: 18054469)
1. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.
Córdoba S; Rodero L; Vivot W; Abrantes R; Davel G; Vitale RG
Int J Antimicrob Agents; 2008 Feb; 31(2):171-4. PubMed ID: 18054469
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
3. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Ortoneda M; Capilla J; Javier Pastor F; Pujol I; Guarro J
Diagn Microbiol Infect Dis; 2004 Jan; 48(1):69-71. PubMed ID: 14761725
[TBL] [Abstract][Full Text] [Related]
4. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
5. In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.
Venturini TP; Rossato L; Spader TB; Tronco-Alves GR; Azevedo MI; Weiler CB; Santurio JM; Alves SH
Diagn Microbiol Infect Dis; 2011 Oct; 71(2):126-30. PubMed ID: 21840673
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi.
Garcia-Effron G; Gomez-Lopez A; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2004 Jun; 53(6):1086-9. PubMed ID: 15102749
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
Lewis RE; Wiederhold NP; Klepser ME
Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
[TBL] [Abstract][Full Text] [Related]
8. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
9. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods.
Iqbal NJ; Boey A; Park BJ; Brandt ME
Diagn Microbiol Infect Dis; 2008 Nov; 62(3):348-50. PubMed ID: 18707841
[TBL] [Abstract][Full Text] [Related]
10. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp.
Spader TB; Venturini TP; Cavalheiro AS; Mahl CD; Mario DN; Lara VM; Santurio J; Alves SH
Mycoses; 2011 Mar; 54(2):131-6. PubMed ID: 19780977
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.
Alastruey-Izquierdo A; Cuenca-Estrella M; Monzón A; Mellado E; Rodríguez-Tudela JL
J Antimicrob Chemother; 2008 Apr; 61(4):805-9. PubMed ID: 18263569
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
14. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.
Shalit I; Shadkchan Y; Mircus G; Osherov N
Med Mycol; 2009; 47(5):457-62. PubMed ID: 18720217
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
[TBL] [Abstract][Full Text] [Related]
16. [Activity of itraconazole against clinical isolates of Aspergillus spp. and Fusarium spp. determined by the M38-P NCCLS method].
Carrillo-Muñoz AJ; Quindós G; Ruesga M; Brió S; del Valle O; Rodríguez V; Hernández-Molina JM; Cantón E; Pemán J; Santos P
Rev Esp Quimioter; 2001 Sep; 14(3):281-5. PubMed ID: 11753450
[TBL] [Abstract][Full Text] [Related]
17. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium.
Spader TB; Venturini TP; Rossato L; Denardi LB; Cavalheiro PB; Botton SA; Santurio JM; Alves SH
Rev Iberoam Micol; 2013; 30(3):200-4. PubMed ID: 23402831
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii.
Zhang X; Huang H; Feng P; Zhang J; Zhong Y; Xue R; Xie Z; Li M; Xi L
Eur J Dermatol; 2011; 21(4):573-6. PubMed ID: 21865116
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
